Skip to main content


13 result(s) for 'author#Johannes Boltze' within BMC

Page 1 of 1

Sort by: Relevance | Date

  1. From November 2nd - 4th 2012, the 4th NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. Again more than 60 participants, predominantly at the doctoral student or postdoc level, gathered to share th...

    Authors: Ralf A Linker, Sven G Meuth, Tim Magnus, Thomas Korn and Christoph Kleinschnitz
    Citation: Experimental & Translational Stroke Medicine 2012 4:22
  2. Sterile inflammation is a substantial element of post-stroke pathophysiology with the determination of autoimmunity versus tolerance being one of its most important aspects. It is believed that this determinat...

    Authors: Claudia Pösel, Anna Uri, Isabell Schulz, Johannes Boltze, Gesa Weise and Daniel-Christoph Wagner
    Citation: Experimental & Translational Stroke Medicine 2014 6:11
  3. The pathophysiology of sterile inflammation following focal ischemic stroke is complex and not fully understood, but there is growing evidence that it offers several therapeutic options beyond the hitherto exi...

    Authors: Karoline Möller, Tobias Stahl, Johannes Boltze and Daniel-Christoph Wagner
    Citation: Experimental & Translational Stroke Medicine 2012 4:20
  4. The 7th International Symposium on Neuroprotection and Neurorepair was held from May 2nd to May 5th, 2012 in Potsdam, Germany. The symposium, which directly continues the successful Magdeburg meeting series, attr...

    Authors: Johannes Boltze, Christoph Kleinschnitz, Klaus G Reymann, Georg Reiser, Daniel-Christoph Wagner, Alexander Kranz and Dominik Michalski
    Citation: Experimental & Translational Stroke Medicine 2012 4:14
  5. One of the most promising options for treatment of stroke using adult stem cells are human umbilical cord blood (HUCB) cells that were already approved for therapeutic efficacy in vivo. However, complexity of ani...

    Authors: Susann Hau, Doreen M Reich, Markus Scholz, Wilfried Naumann, Frank Emmrich, Manja Kamprad and Johannes Boltze
    Citation: BMC Neuroscience 2008 9:30
  6. After promising results in experimental stroke, normobaric (NBO) or hyperbaric oxygenation (HBO) have recently been discussed as co-medication with tissue plasminogen activator (tPA) for improving outcome. Thi...

    Authors: Dominik Michalski, Johann Pelz, Christopher Weise, Johannes Kacza, Johannes Boltze, Jens Grosche, Manja Kamprad, Dietmar Schneider, Carsten Hobohm and Wolfgang Härtig
    Citation: Experimental & Translational Stroke Medicine 2011 3:5
  7. The therapeutic capacity of human umbilical cord blood mononuclear cells (HUCB-MNC) and stem cells derived thereof is documented in animal models of focal cerebral ischemia, while mechanisms behind the reducti...

    Authors: Doreen M Reich, Susann Hau, Tobias Stahl, Markus Scholz, Wilfried Naumann, Frank Emmrich, Johannes Boltze and Manja Kamprad
    Citation: BMC Neuroscience 2008 9:91
  8. Bone marrow-derived mononuclear cells (BM MNC) have been effectively used to treat experimental stroke. Most of the preclinical trials have been performed in young and healthy laboratory animals, even though a...

    Authors: Daniel-Christoph Wagner, Mitja Bojko, Myriam Peters, Marlene Lorenz, Cornelia Voigt, Alexander Kaminski, Dirk Hasenclever, Markus Scholz, Alexander Kranz, Gesa Weise and Johannes Boltze
    Citation: Experimental & Translational Stroke Medicine 2012 4:17
  9. Cerebral small vessel disease (cSVD) is one of the most prevalent neurological disorders. The progressive remodeling of brain microvessels due to arterial hypertension or other vascular risk factors causes sub...

    Authors: Daniel Kaiser, Gesa Weise, Karoline Möller, Johanna Scheibe, Claudia Pösel, Sebastian Baasch, Matthias Gawlitza, Donald Lobsien, Kai Diederich, Jens Minnerup, Alexander Kranz, Johannes Boltze and Daniel-Christoph Wagner
    Citation: Acta Neuropathologica Communications 2014 2:169
  10. In ischemic stroke, blood-brain barrier (BBB) regulations, typically involving matrix metalloproteinases (MMPs) and inhibitors (TIMPs) as mediators, became interesting since tissue plasminogen activator (tPA)-...

    Authors: Dominik Michalski, Carsten Hobohm, Christopher Weise, Johann Pelz, Marita Heindl, Manja Kamprad, Johannes Kacza and Wolfgang Härtig
    Citation: Medical Gas Research 2012 2:2
  11. Intra-arterial cell infusion is an efficient delivery route with which to target organs such as the ischemic brain. However, adverse events including microembolisms and decreased cerebral blood flow were recen...

    Authors: Li-li Cui, Erja Kerkelä, Abdulhameed Bakreen, Franziska Nitzsche, Anna Andrzejewska, Adam Nowakowski, Miroslaw Janowski, Piotr Walczak, Johannes Boltze, Barbara Lukomska and Jukka Jolkkonen
    Citation: Stem Cell Research & Therapy 2015 6:11
  12. Since several neuroprotectives failed to reproduce promising preclinical results under clinical conditions, efforts emerged to implement clinically relevant endpoints in animal stroke studies. Thereby, insuffi...

    Authors: Dominik Michalski, Christopher Weise, Carsten Hobohm, Lea Küppers-Tiedt, Johann Pelz, Dietmar Schneider, Johannes Kacza and Wolfgang Härtig
    Citation: Experimental & Translational Stroke Medicine 2012 4:7
  13. Disease models are useful for prospective studies of pathology, identification of molecular and cellular mechanisms, pre-clinical testing of interventions, and validation of clinical biomarkers. Here, we revie...

    Authors: Atticus H. Hainsworth, Stuart M. Allan, Johannes Boltze, Catriona Cunningham, Chad Farris, Elizabeth Head, Masafumi Ihara, Jeremy D. Isaacs, Raj N. Kalaria, Saskia A. M. J. Lesnik Oberstein, Mark B. Moss, Björn Nitzsche, Gary A. Rosenberg, Julie W. Rutten, Melita Salkovic-Petrisic and Aron M. Troen
    Citation: BMC Medicine 2017 15:16